Open Access

Long non‑coding RNA USP30‑AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA‑299‑3p and thereby overexpressing PTP4A1

  • Authors:
    • Mengyue Chen
    • Yugang Chi
    • Hongwei Chen
    • Limei Zhao
  • View Affiliations

  • Published online on: April 29, 2021     https://doi.org/10.3892/ol.2021.12766
  • Article Number: 505
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

USP30 antisense RNA 1 (USP30‑AS1) has been studied in bladder urothelial carcinoma. However, the detailed role of USP30‑AS1 in cervical cancer remains to be elucidated. Therefore, the present study determined whether USP30‑AS1 is implicated in cervical cancer malignancy, and investigated relevant molecular mechanisms. USP30‑AS1 expression was measured via reverse transcription‑quantitative PCR. Functional experiments, including the Cell Counting Kit‑8 assay, flow cytometry, Transwell migration and invasion assays, and mouse tumour model, were performed in order to elucidate the roles of USP30‑AS1. The target of USP30‑AS1 was predicted using bioinformatics analysis, which was further verified via RNA immunoprecipitation and luciferase reporter assays. Herein, USP30‑AS1 overexpression was detected in cervical cancer sample data from The Cancer Genome Atlas and our cohort. Patients with cervical cancer expressing high levels of USP30‑AS1 exhibited shorter overall survival than those with low USP30‑AS1 expression. In vitro and in vivo experiments revealed that USP30‑AS1 interference promoted cell apoptosis; restrained cell proliferation, migration and invasion in vitro, and hindered tumour growth in vivo. Mechanistically, USP30‑AS1 competed for microRNA‑299‑3p (miR‑299‑3p) in cervical cancer and lowered the regulatory actions of miR‑299‑3p on protein tyrosine phosphatase type IVA (PTP4A1), resulting in PTP4A1 overexpression. Furthermore, rescue experiments confirmed that miR‑299‑3p interventions or exogenous PTP4A1 could counteract the cancer‑inhibiting actions of USP30‑AS1 silencing on cervical cancer cells. In conclusion, the miR‑299‑3p/PTP4A1 axis is the downstream effector of USP30‑AS1 in cervical cancer, forming the USP30‑AS1/miR‑299‑3p/PTP4A1 pathway. This newly identified competing endogenous RNA pathway may offer a novel theoretical and experimental basis for developing promising new strategies for the targeted therapy of cervical cancer.
View Figures
View References

Related Articles

Journal Cover

July-2021
Volume 22 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen M, Chi Y, Chen H and Zhao L: Long non‑coding RNA USP30‑AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA‑299‑3p and thereby overexpressing PTP4A1. Oncol Lett 22: 505, 2021.
APA
Chen, M., Chi, Y., Chen, H., & Zhao, L. (2021). Long non‑coding RNA USP30‑AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA‑299‑3p and thereby overexpressing PTP4A1. Oncology Letters, 22, 505. https://doi.org/10.3892/ol.2021.12766
MLA
Chen, M., Chi, Y., Chen, H., Zhao, L."Long non‑coding RNA USP30‑AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA‑299‑3p and thereby overexpressing PTP4A1". Oncology Letters 22.1 (2021): 505.
Chicago
Chen, M., Chi, Y., Chen, H., Zhao, L."Long non‑coding RNA USP30‑AS1 aggravates the malignant progression of cervical cancer by sequestering microRNA‑299‑3p and thereby overexpressing PTP4A1". Oncology Letters 22, no. 1 (2021): 505. https://doi.org/10.3892/ol.2021.12766